JBM (Healthcare) (HKSE:02161) Tax Provision : HK$-30.6 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is JBM (Healthcare) Tax Provision?

JBM (Healthcare)'s tax provision for the six months ended in Sep. 2024 was HK$-19.1 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was HK$-30.6 Mil.

JBM (Healthcare) Tax Provision Historical Data

The historical data trend for JBM (Healthcare)'s Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JBM (Healthcare) Tax Provision Chart

JBM (Healthcare) Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Tax Provision

Get a 7-Day Free Trial

-9.67

-11.06

-7.42

-13.57

-27.68

JBM (Healthcare) Semi-Annual Data
	Mar18	Mar19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Tax Provision	Get a 7-Day Free Trial							-5.56	-8.01	-16.20	-11.48	-19.11

JBM (Healthcare) Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-30.6 Mil.

JBM (Healthcare) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JBM (Healthcare) Ltd (HKSE:02161) » Definitions » Tax Provision

Traded in Other Exchanges

N/A

Address

108 Wai Yip Street, Units 808-811, 8 floor, C-Bons International Centre, Kwun Tong, Kowloon, Hong Kong, HKG

Website

https://www.jbmhealthcare.com.hk

JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.

Executives

Sum Kwong Yip, Derek
Queenshill Development Limited
Ubs Trustees (b.v.i.) Limited
Kingshill Development Group Inc
Lincoln's Hill Development Limited
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si
New Heritage Healthcare Limited	2101 Beneficial owner
Gavett Limited	2201 Interest of corporation controlled by you
United Islands Group Limited	2201 Interest of corporation controlled by you
Fortstar Limited	2201 Interest of corporation controlled by you
Tao Richard	2201 Interest of corporation controlled by you
Hon Hing Tong Patricia	2202 Interest of your spouse
Tao Paul	2201 Interest of corporation controlled by you
Choi Siu Ping	2202 Interest of your spouse
Longjin Investments Limited	2101 Beneficial owner

JBM (Healthcare) Headlines

No Headlines